ZD 9379

Key Product Details

Product Description

ZD 9379 is a NMDA receptor antagonist; acts at glycine site. Neuroprotective; reduces infarct size and frequency of spreading depressions in a rat model of ischemic stroke. Brain penetrant.

Licensing Information

Sold for research purposes under agreement from AstraZeneca

Product Specifications for ZD 9379

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for ZD 9379

The following data is based on the product molecular weight 383.79.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	5.21 mL	26.06 mL	52.11 mL
2.5 mM	1.04 mL	5.21 mL	10.42 mL
5 mM	0.52 mL	2.61 mL	5.21 mL
25 mM	0.10 mL	0.52 mL	1.04 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Takano Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Stroke. 1997 PMID: 9183359
• Tatlisumak A glycine antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Acta.Neurochir.Suppl. 2000 PMID: 11450037
• Bare Pyridazino[4,5-b]quinolinediones: a series of novel glycine site NMDA antagonists with potent in vitro and in vivo properties. Abstracts of Papers of the ACS

Product Documents for ZD 9379